-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical Group Receives Two Prestigious Awards from the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce.
Category:
Time：2023-03-27
On March 26, the annual summit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber, jointly hosted by the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber, the Management Committee of Qingdao High-tech Industrial Development Zone, and the Qingdao Federation of Industry and Commerce, was held in Qingdao. During the event, the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber released a series of rankings for the most influential companies in China's pharmaceutical industry for the 2021-2022 period. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: Top 100 Chinese Pharmaceutical Manufacturers and Pioneer Enterprise in Independent Innovation in China's Pharmaceutical Industry.
On March 26, the annual summit of the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, jointly hosted by the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce, the Management Committee of Qingdao High-Tech Industrial Development Zone, and the Qingdao Federation of Industry and Commerce, was held in Qingdao. During the summit, the All-China Federation of Industry and Commerce Pharmaceutical Industry Chamber of Commerce released a series of rankings for the most influential companies in China’s pharmaceutical industry for the 2021-2022 period. Shijiazhuang Sihua Pharmaceutical Group was honored with two prestigious awards: Top 100 Chinese Pharmaceutical Manufacturers and Pioneer Enterprise in Independent Innovation in China’s Pharmaceutical Industry.
In recent years, Shijiazhuang Fourth Pharmaceutical Group has fully leveraged its own strengths, strategically aligning its innovation efforts with the industrial chain. The group has continuously accelerated its pace of innovation in specialty generic drugs, innovative pharmaceuticals, active pharmaceutical ingredients, and pharmaceutical packaging materials. A phased innovation development model—“research and develop a batch, commercialize a batch, and reserve a batch”—has gradually taken shape, enabling synchronized advancement across the entire drug R&D and market transformation value chain. The continuous optimization of product structure and the steady enhancement of development capabilities have powerfully propelled the company’s growth, improving quality and efficiency and helping it move up the value chain to higher-end segments.
It is reported that the 2021-2022 China Pharmaceutical Industry’s Most Influential List was compiled by the Pharmaceutical Industry Chamber of the All-China Federation of Industry and Commerce, using metrics such as performance indicators, independent innovation capabilities, social responsibility index, and professionalization level as evaluation criteria. To date, this selection event has been held for nine consecutive sessions, aiming to promote the development of the pharmaceutical industry and enable winning enterprises and entrepreneurs to maximize their influence. With its comprehensive coverage of the entire industry chain, strong representativeness, and high level of participation, the selection event has become one of China’s authoritative branding initiatives in the pharmaceutical industry, attracting widespread attention from companies and entrepreneurs across the sector.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license